NR1H4 and Cirrhosis: Diminished luminal BA availability in cirrhosis provokes a reduction in intestinal FXR signaling which seems, at least partly, to mediate the gut barrier disruption in cirrhosis, as FXR-agonists reduce GBT via the portal-venous route to the liver (13).